MEDICATION SAFETY

FDA’s AERS provides surprising look at statin class side effects, study shows

Findings culled from a new method for aggregating and making sense of data in the FDA’s Adverse Event Reporting System present a surprising glimpse at the postmarketing adverse event data for statins. » More

Boehringer says about 50 deaths related to stroke prevention pill

Boehringer Ingelheim's new stroke prevention pill Pradaxa (dabigatran) has been linked to about 50 deaths from bleeding across the world since its market launch, the company said recently. » More

CLINICAL NEWS

Letrozole more effective than tamoxifen at reducing breast cancer recurrence, mortality in postmenopausal women

When compared with tamoxifen monotherapy, letrozole (Femara, Novartis) monotherapy was more effective at preventing breast cancer recurrence and improving survival among postmenopausal women with endocrine-responsive early breast cancer, according to a long-term follow-up published online October 21 in Lancet Oncology. » More

Risk assessment important in VTE prophylaxis for medical inpatients

Hospitalized nonsurgical patients (medical patients and those with acute stroke) should receive pharmacologic venous thromboembolism prophylaxis, unless the risk for bleeding outweighs the likely benefit, according to a new Clinical Practice Guideline from the American College of Physicians. » More

FDA ACTIONS

FDA approves bupivacaine injection for post-surgical pain management

FDA has approved bupivacaine liposome injectable suspension (Exparel, Pacira Pharmaceuticals) 1.3% for administration into the surgical site to produce post-surgical analgesia. » More

ASSOCIATION NEWS

Ethics Colloquium at ASHP Midyear Clinical Meeting will cover “grey market” medications, dilemmas

Pharmacists being pressured by patients for “grey market” medications is one of the issues that will be discussed at the Joseph A. Oddis Ethics Colloquium during the American Society of Health System Pharmacists’ Midyear Clinical Meeting & Exhibition to be held in New Orleans, La., on December 4. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•	Anticoagulation update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.